Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Habib Khan

Vascular Surgery Neptune, NJ Medical Doctor

NPI 1437393063 CMS profile 1344721

3700 Route 33, 2Nd Floor-Suite C, Neptune, NJ 07753

Open in the dashboard

General payments

$25,850

238 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Habib Khan of Neptune, NJ is reported in the CMS Open Payments database as having received $25,850 across 238 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,478 36
2024 General $2,523 24
2023 General $1,474 28
2022 General $2,824 45
2021 General $1,153 35
2020 General $3,891 38
2019 General $5,506 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Habib Khan
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Habib Khan were reported at $8,478. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Habib Khan Vascular Surgery median Middle half National median
2019 $5,506 $796 $226–$2,363 $163
2020 $3,891 $348 $118–$1,110 $114
2021 $1,153 $471 $158–$1,421 $132
2022 $2,824 $725 $222–$2,183 $149
2023 $1,474 $836 $257–$2,440 $160
2024 $2,523 $909 $252–$2,619 $164
2025 $8,478 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $8,019 36 payments
  2. Bard Peripheral Vascular, Inc. $7,403 26 payments
  3. W. L. Gore & Associates, Inc. $2,502 41 payments
  4. Silk Road Medical, Inc. $1,930 17 payments
  5. Medtronic, Inc. $1,835 27 payments
  6. Endologix, Inc. $1,265 7 payments
  7. Bolton Medical Inc $698 13 payments
  8. Inari Medical, Inc. $664 8 payments
  9. Musculoskeletal Transplant Foundation Inc. $248 9 payments
  10. Cardiovascular Systems Inc. $238 12 payments
  11. Other $1,048 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,251 207 payments
  2. Consulting Fee $8,744 4 payments
  3. Travel and Lodging $4,055 26 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,800 1 payment
Products named General payments · program years 2019–2025
  1. General - Therapies $7,104 9 payments
  2. LUTONIX Peripheral Vascular $3,818 2 payments
  3. LUTONIX BD Interventional - Peripheral Intervention $3,045 4 payments
  4. ENROUTE Transcarotid Stent $1,194 11 payments
  5. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,194 11 payments
  6. Alto Abdominal Stent Graft System $1,068 5 payments
  7. ELLIPSYS VASCULAR ACCESS SYSTEM $1,040 9 payments
  8. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $1,019 6 payments
  9. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,019 6 payments
  10. FLOWTRIEVER CATHETER, S $817 9 payments
  11. Other $10,452 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

98

Median for Vascular Surgery: 122

Drug cost

$14,471

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 17 $13,796
Clopidogrel Clopidogrel Bisulfate Brand 81 $675

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 122 billing codes

Paid by Medicare

$801,710

Of which drugs: $296

Medicare patients

526

Average age 76

Services billed

4,336

246 women, 280 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 58%
Diabetes 55%
Chronic kidney disease 49%
Heart failure 44%
Atrial fibrillation 40%
COPD 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 27 2,159 $226

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $15
$15 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

238 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record